DCTHHealthcare · Medical DevicesThe 5 Wall Street analysts covering Delcath Systems, Inc. hold a median 12-month price target of $22 — +28.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Delcath Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (100): The business earns solid, repeatable profits on what it owns.
Growth (36): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DCTH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +28.4% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $30 → $32 |
| 6 Aug 2026 | BTIG | Maintains | Buy | $17 → $21 |
| 26 Feb 2026 | BTIG | Maintains | Buy | $23 → $19 |
| 26 Feb 2026 | BTIG | Maintains | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2025 | Stephens & Co. | Maintains | Overweight | — |
| 4 Nov 2025 | BTIG | Reiterates | Buy | — |
| 21 Oct 2025 | Canaccord Genuity | Maintains | Buy | — |
| 20 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 June 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 23 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Jan 2025 | Craig-Hallum | Maintains | Buy | — |
| 14 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Oct 2024 | Canaccord Genuity | Maintains | Buy | $21 |
| 18 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | $22 |
| 6 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2024 | Stephens & Co. | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DCTH appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 22% of US stocks
Cheaper than 23% of US stocks
Cheaper than 98% of US stocks
Higher than 70% of US stocks
Higher than 34% of US stocks
Higher than 96% of US stocks
Higher than 61% of US stocks
Higher than 48% of US stocks
Higher than 45% of US stocks
Higher than 40% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Delcath Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlighted Delcath Systems (DCTH) as a stock well positioned to maintain its recent uptrend, noting it passed their "Recent Price Strength" screening criteria.
Why it matters — DCTH watchers would care because the article suggests the stock has strong recent price momentum that could continue.
Zacks Investment Research published an article examining whether Delcath Systems, Inc. (DCTH) qualifies as a top pick for momentum investors, framing the stock as a great momentum opportunity. The piece sets out to assess DCTH's attributes for momentum-stock selection criteria.
Why it matters — The article highlights DCTH as a notable momentum stock, which could draw attention from investors who screen for momentum-based opportunities.
Zacks reports that the average of Wall Street analyst price targets for Delcath Systems (DCTH) implies a potential upside of about 42.8%. The article also notes that while this price-target metric is of questionable effectiveness, a positive trend in earnings estimate revisions could point to upside for the stock.
Why it matters — A DCTH watcher would care because the piece highlights both an analyst-derived upside estimate and positive earnings estimate revisions, both of which may signal improving market sentiment toward the stock.
Delcath Systems reported strong second-quarter revenue and earnings, with its shares surging as a result. The article notes that Q3 seasonality is expected to be less pronounced in 2026, which is expected to keep growth robust in the second half of the year.
Why it matters — DCTH watchers would care because the article suggests that recent quarterly headwinds are fading and that the company's growth is expected to remain strong through the second half of 2026.
Delcath Systems held its Q2 2026 earnings call, during which management discussed the company's quarterly financial results and business developments.
Why it matters — DCTH watchers look to earnings calls for management's commentary on commercial progress, pipeline updates, and financial health.
The 5 Wall Street analysts covering Delcath Systems, Inc. have a median 12-month price target of $22, with estimates ranging from $21 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Delcath Systems, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Delcath Systems, Inc. 96 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Delcath Systems, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +28.4% from the last close, and Ticker Nerd's factor model ranks Delcath Systems, Inc. 96 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Delcath Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $32 over the next 12 months.
Delcath Systems, Inc. returned +64.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Delcath Systems Inc. is a medical device company focused on providing treatment options for primary and metastatic liver cancers through its innovative technologies.
The most recent item we track (Zacks Investment Research, 12 Aug 2026): "Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why". Zacks Investment Research highlighted Delcath Systems (DCTH) as a stock well positioned to maintain its recent uptrend, noting it passed their "Recent Price Strength" screening criteria.
Delcath Systems Inc. is a medical device company focused on providing treatment options for primary and metastatic liver cancers through its innovative technologies. Central to their product offerings is the percutaneous hepatic perfusion (PHP) system, which enables targeted delivery of high-dose chemotherapy directly to the liver. This approach aims to maximize impact on cancer cells while minimizing systemic exposure and related side effects. Delcath Systems Inc. operates primarily within the healthcare sector, impacting the medical device and oncology industries. The company engages with hospitals, medical professionals, and patients, contributing to evolving treatment protocols for liver cancer. By developing interventional medical solutions, Delcath Systems Inc. plays a significant role in advancing targeted cancer therapies and enhancing the arsenal of available tools in oncology. Headquartered in New York, the company is part of a growing movement towards personalized and precision medicine, seeking to improve patient outcomes through targeted therapeutic interventions.
CEO Mr. Gerard J. Michel MBA, MS · 156 employees · United States · https://www.delcath.com